Lario Therapeutics receives “Company Making a Difference Award” from CDLK5 Forum, recognising its unique approach to precision medicine for genetic epilepsies

  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 71%

United States News News

United States United States Latest News,United States United States Headlines

“CDLK5 Forum Award for Excellence - Company Making a Difference 2023 Pre-clinical” presented by the Loulou Foundation at the CDKL5 Forum, 6th-7th November in London

Nov 7 2023 Lario Therapeutics , a biopharmaceutical company developing first-in-class precision medicines that are targeting disease-modifying treatments for severe neurological disorders, has received the “CDLK5 Forum Award for Excellence - Company Making a Difference 2023 Pre-clinical” from the Loulou Foundation at the annual CDKL5 Forum. The award is in recognition of its development of a validated, precision medicine approach in genetic epilepsies.

Henning Steinhagen, Ph.D., Co-Founder and CEO of Lario Therapeutics, commented: “We are honored and thank the Loulou Foundation for their recognition of our approach which we hope will have a positive impact on patients affected by CDKL5 Deficiency Disorder. Our target, CaV2.3, represents one of the few newly validated precision medicine approaches in neurology and has a significant potential in severe epileptic conditions and other neurological disorders including Parkinson’s disease.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 19. in US

United States United States Latest News, United States United States Headlines